Detail akcie ABVC BioPharma Rg online

Business Summary: ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
Financial Summary: BRIEF: For the three months ended 31 March 2025, ABVC Biopharma Inc revenues decreased from $1K to $0K. Net loss decreased 70% to $842K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Stock-based compensation decrease of 98% to $49K (expense), Selling, general and administrative expe decrease of 22% to $498K (expense).